$20 Million

Nivalis Therapeutics

At-the-market Offering

Developer of novel class of disease modifying therapies designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).